MMIT Report Highlights Coverage for Growth Hormone Deficiency Treatments

MMIT in a new report analyzes varying coverage decisions by payers for growth hormone deficiency treatments.

“The market is trending toward the development of long-acting growth hormone drugs that can be administered weekly or biweekly instead of currently marketed daily growth hormones,” a description for the report states. “This change is believed to help increase adherence and compliance to therapy.”

To find out how to download this report, click here.